{"doi":"10.1101/2021.01.09.21249145","title":"Plasma β-amyloid in mild behavioural impairment – neuropsychiatric symptoms on the Alzheimer’s continuum","abstract":"Abstract Introduction Simple markers are required to recognize older adults at higher risk for neurodegenerative disease. Mild behavioural impairment (MBI) and plasma β-amyloid (Aβ) have been independently implicated in the development of incident cognitive decline and dementia. Here we studied the associations between MBI and plasma Aβ 42 /Aβ 40 . Methods Participants with normal cognition (n = 86) or mild cognitive impairment (n = 53) were selected from the Alzheimer’s Disease Neuroimaging Initiative. MBI scores were derived from Neuropsychiatric Inventory items. Plasma Aβ 42 /Aβ 40 ratios were assayed using mass spectrometry. Linear regressions were fitted to assess the association between MBI total score as well as MBI domain scores with plasma Aβ 42 /Aβ 40 . Results Lower plasma Aβ 42 /Aβ 40 was associated with higher MBI total score ( p = 0.04) and greater affective dysregulation ( p = 0.04), but not with impaired drive/motivation ( p = 0.095) or impulse dyscontrol ( p = 0.29) MBI domains. Conclusion In persons with normal cognition or mild cognitive impairment, MBI was associated with low plasma Aβ 42 /Aβ 40 . Incorporating MBI into case detection can help capture preclinical and prodromal Alzheimer’s disease.","journal":"medRxiv","year":2021,"id":215726,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9488,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":811032,"name":"Hung‐Yu Chen","orcid":"0000-0001-8562-2113","position":1,"is_corresponding":false},{"id":268012,"name":"Sascha Gill","orcid":"0000-0001-9978-8691","position":2,"is_corresponding":false},{"id":811712,"name":"James Naude","orcid":null,"position":3,"is_corresponding":false},{"id":268016,"name":"Eric E. Smith","orcid":"0000-0003-3956-1668","position":4,"is_corresponding":false},{"id":3086,"name":"Zahinoor Ismail","orcid":"0000-0002-5529-3731","position":5,"is_corresponding":false},{"id":243718,"name":"for the Alzheimer’s Disease Neuroimaging Initiative","orcid":null,"position":6,"is_corresponding":false},{"id":811031,"name":"Ruxin Miao","orcid":"0000-0002-7308-3797","position":0,"is_corresponding":true}],"reference_count":65,"raw_metadata":null,"created_at":"2026-07-18T23:53:00.192353Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}